ETLI:F Legal & General UCITS ETF Plc - L&G Pharma Breakthrough UCITS ETF

EUR 9.02 0.10 1.07551
Icon

Legal & General UCITS ETF Plc - L&G Pharma Breakthrough UCITS ETF (ETLI:F) Stock Analysis and Price Targets

ETF | Others | F
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Very Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

EUR 9.02

+0.10 (+1.08)%

EUR 0.03B

N/A

N/A

N/A

Icon

ETLI:F

Legal & General UCITS ETF Plc - L&G Pharma Breakthrough UCITS ETF (EUR)
ETF | F
EUR 9.02
0.00 0
Take a Tour
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Very Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

EUR 0.03B

N/A

EUR 9.02

Legal & General UCITS ETF Plc - L&G Pharma Breakthrough UCITS ETF (ETLI:F) Stock Forecast

N/A

Based on the Legal & General UCITS ETF Plc - L&G Pharma Breakthrough UCITS ETF stock forecast from 0 analysts, the average analyst target price for Legal & General UCITS ETF Plc - L&G Pharma Breakthrough UCITS ETF is not available over the next 12 months. Legal & General UCITS ETF Plc - L&G Pharma Breakthrough UCITS ETF’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Legal & General UCITS ETF Plc - L&G Pharma Breakthrough UCITS ETF is Very Bearish, which is based on 0 positive signals and 3 negative signals. At the last closing, Legal & General UCITS ETF Plc - L&G Pharma Breakthrough UCITS ETF’s stock price was EUR 9.02. Legal & General UCITS ETF Plc - L&G Pharma Breakthrough UCITS ETF’s stock price has changed by +0.09% over the past week, -1.12% over the past month and -12.68% over the last year.

No recent analyst target price found for Legal & General UCITS ETF Plc - L&G Pharma Breakthrough UCITS ETF
No recent average analyst rating found for Legal & General UCITS ETF Plc - L&G Pharma Breakthrough UCITS ETF

Company Overview Legal & General UCITS ETF Plc - L&G Pharma Breakthrough UCITS ETF

NA

N/A

N/A

N/A

N/A

EUR

Germany

N/A

N/A

N/A

0.49 %

Adjusted Closing Price for Legal & General UCITS ETF Plc - L&G Pharma Breakthrough UCITS ETF (ETLI:F)

Loading...

Unadjusted Closing Price for Legal & General UCITS ETF Plc - L&G Pharma Breakthrough UCITS ETF (ETLI:F)

Loading...

Share Trading Volume for Legal & General UCITS ETF Plc - L&G Pharma Breakthrough UCITS ETF Shares

Loading...

Compare Performance of Legal & General UCITS ETF Plc - L&G Pharma Breakthrough UCITS ETF Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for ETLI:F

Top Sectors

N/A

Top Regions

N/A

Valuation Growth & Performance

  • N/A

  • N/A

  • N/A

  • 0.00

  • 0.00

  • 0.00

  • -5.29%

  • -5.05%

  • -0.39%

  • 0%

Stocks Similar To Legal & General UCITS ETF Plc - L&G Pharma Breakthrough UCITS ETF (Sector: Others )

Symbol Name Mer Price(Change) Market Cap
PRAJ:F
Amundi Index Solutions - Amund.. 0.00 % +0.02 (+0.05%) EUR139.20B

ETFs Containing ETLI

Symbol Name ETLI's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Legal & General UCITS ETF Plc - L&G Pharma Breakthrough UCITS ETF (ETLI:F) Stock

Stock Target Advisor's fundamental analysis for Legal & General UCITS ETF Plc - L&G Pharma Breakthrough UCITS ETF's stock is Very Bearish.

ETLI:F stock's dividend yield is 0.94%. Our analysis grades ETLI:F stock's dividend yield at F. This means that ETLI:F stock's dividend yield is above 7% of the stocks in the Others sector in the F exchange. Based on this ETLI:F may be a poor dividend stock for its sector.

Unfortunately we do not have enough data on ETLI:F's stock to indicate what its average analyst target is.

Unfortunately we do not have enough data on ETLI:F's stock to indicate if its overvalued.

The last closing price of ETLI:F's stock was EUR 9.02.

The most recent market capitalization for ETLI:F is EUR 0.03B.

Unfortunately we do not have enough analyst data on ETLI:F's stock to indicate whether its price will go up or not.

We can't find any ETFs which contains Legal & General UCITS ETF Plc - L&G Pharma Breakthrough UCITS ETF's stock.

Sorry, we do not have any data on the number of employees for Legal & General UCITS ETF Plc - L&G Pharma Breakthrough UCITS ETF.

Sorry we do not have any infomation available on Legal & General UCITS ETF Plc - L&G Pharma Breakthrough UCITS ETF's address.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...